<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zavvar TS</submitter><funding>Austrian Science Fund FWF</funding><pagination>278</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9959130</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(2)</volume><pubmed_abstract>Different attempts have been made in the past two decades to develop radiolabeled peptide conjugates with enhanced pharmacokinetic properties in order to improve the application for tumor imaging and peptide receptor radionuclide therapy (PRRT), which targets the cholecystokinin-2 receptor (CCK2R). In this paper, the influence of different side chain and peptide bond modifications has been explored for the minigastrin analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(&lt;i>N&lt;/i>-Me)Nle-Asp-1Nal-NH&lt;sub>2&lt;/sub> (DOTA-MGS5). Based on this lead structure, five new derivatives were synthesized for radiolabeling with trivalent radiometals. Different chemical and biological properties of the new derivatives were analyzed. Receptor interaction of the peptide derivatives and cell internalization of the radiolabeled p</pubmed_abstract><journal>Pharmaceuticals (Basel, Switzerland)</journal><pubmed_title>Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.</pubmed_title><pmcid>PMC9959130</pmcid><funding_grant_id>P 27844</funding_grant_id><funding_grant_id>DOC 110</funding_grant_id><pubmed_authors>Zavvar TS</pubmed_authors><pubmed_authors>Castel H</pubmed_authors><pubmed_authors>Klingler M</pubmed_authors><pubmed_authors>Hormann AA</pubmed_authors><pubmed_authors>Rangger C</pubmed_authors><pubmed_authors>Desrues L</pubmed_authors><pubmed_authors>Summer D</pubmed_authors><pubmed_authors>Gandolfo P</pubmed_authors><pubmed_authors>von Guggenberg E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.</name><description>Different attempts have been made in the past two decades to develop radiolabeled peptide conjugates with enhanced pharmacokinetic properties in order to improve the application for tumor imaging and peptide receptor radionuclide therapy (PRRT), which targets the cholecystokinin-2 receptor (CCK2R). In this paper, the influence of different side chain and peptide bond modifications has been explored for the minigastrin analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(&lt;i>N&lt;/i>-Me)Nle-Asp-1Nal-NH&lt;sub>2&lt;/sub> (DOTA-MGS5). Based on this lead structure, five new derivatives were synthesized for radiolabeling with trivalent radiometals. Different chemical and biological properties of the new derivatives were analyzed. Receptor interaction of the peptide derivatives and cell internalization of the radiolabeled p</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-08-12T03:05:02.688Z</modification><creation>2025-08-12T03:05:02.688Z</creation></dates><accession>S-EPMC9959130</accession><cross_references><pubmed>37052226</pubmed><doi>10.3390/ph16020278</doi></cross_references></HashMap>